



Asuragen, Inc.
2150 Woodward St., Suite 100
Austin, T.X. 78744
PH: 512 681-5200
T: 877.777.1874
www.asuragen.com

Asuragen to Present at the JPMorgan 26th Annual Healthcare Conference

Austin, Texas – January 3, 2008 – Asuragen, Inc. announced today that it will present at the JPMorgan 26th Annual Healthcare Conference at 4 p.m. PST on Monday, January 7, 2008. Matt Winkler, the company's CEO and CSO, will make the company's presentation.

About Asuragen, Inc.

Asuragen is a fully integrated molecular diagnostics company focused on molecular oncology and early detection of cancer with emphasis on microRNA. Asuragen's current diagnostic product portfolio consists of Signature® Genetic Testing and Oncology Testing products as well as industry leading controls and standards engineered using its patented Armored RNA® technology. Asuragen is empowered with a high level of scientific expertise and assay development along with a well developed business infrastructure, GLP testing services and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, testing, production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting edge clinical products. In addition, Asuragen has a miRNA therapeutics program which it is managing as a separate entity. More information is available at the Company's website: www.asuragen.com.

#

Contact:
Rollie Carlson
President
Asuragen, Inc.
512-681-5211
rcarlson@asuragen.com